Brought to you by 
Agile Therapeutics brings in $40mm through its Series C round
27 May 2014
Executive Summary
Women’s health company Agile Therapeutics Inc. has raised $40mm through its Series C venture round. New backer Aisling Capital led (and contributes a board member) and was joined by current shareholders Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures, and Novitas Capital. Agile has filed an NDA for AG20015 (a contraceptive patch containing levonorgestrel and ethinyl estradiol) and plans to use the proceeds for the eventual launch of the drug candidate and for the continued development of AG890, a Phase I progestin-only contraceptive patch.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Agile Therapeutics brings in $40mm through its Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice